Valeria Fontana

Feasibility and Activity of Concurrent Neoadjuvant Chemotherapy and Radiotherapy in Patients with High-risk Soft-Tissue Sarcoma

Elena Palassini, Sara Pizzamiglio, Emanuela Palmerini, Vittorio Quagliuolo et autres

it, us, es, fr, pl (code pays fourni par la source)

Impact of BRCA pathogenic variants and novel targeted agents on ovarian reserve measured by anti-Müllerian hormone levels in young women with early breast cancer: A biomarker analysis of the PREFER study.

Luca Arecco, Arianna Meacci, Virginia Delucchi, Eva Blondeaux et autres

be, it (code pays fourni par la source)

Endovascular vs conservative treatment in patients with chronic subdural hematomas and mild symptoms: a study protocol for a multicenter randomized controlled trial (EMBOTRIAL-1)

Giancarlo Salsano, Pietro Fiaschi, G Laurà, Mammoliti Sonia et autres

it (code pays fourni par la source)

Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas

Sandro Pasquali, Paola Collini, Cleofé Romagosa, Jean‐Michel Coindre et autres

it, es, fr, us, pl (code pays fourni par la source)

Fertility and ovarian function preservation in young women with breast cancer: A joint analysis of the Joven & Fuerte and PREFER prospective studies

Fernanda Mesa-Chávez, Maria Grazia Razeti, Eva Blondeaux, Alejandra Platas et autres

mx, it (code pays fourni par la source)

Abstract P2-03-02: Fertility and ovarian function preservation in young women with breast cancer: A comparative analysis of two prospective cohort studies in Mexico and Italy

Fernanda Mesa-Chávez, Maria Grazia Razeti, Eva Blondeaux, Alejandra Platas et autres

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial

Andrea Vanzulli, R. Vigorito, Ciriaco Buonomenna, Emanuela Palmerini et autres

it, es, fr, pl (code pays fourni par la source)

Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities.

Andrea Vanzulli, Raffaella Vigorito, Ciriaco Buonomenna, Emanuela Palmerini et autres

it, es, fr, pl (code pays fourni par la source)

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martín‐Broto et autres

it, es, fr, pl (code pays fourni par la source)

Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.

Sandro Pasquali, Paola Collini, Cleofé Romagosa, Jean Michel Coindre et autres

it, es, fr, pl (code pays fourni par la source)

A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.

Elena Palassini, Sara Pizzamiglio, Emanuela Palmerini, Vittorio Quagliuolo et autres

it, es, fr, pl (code pays fourni par la source)

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martín‐Broto et autres

it, es, fr, pl (code pays fourni par la source)